Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great science...I wish management would sell this to a big Pharma company. They have no money and no idea how to raise money to fund the clinical trials, other than R/S and dilute. There has been no return here in a very long time. The share price is down about 85% since the last split of that tells you anything.
* * $RNN Video Chart 01-23-2019 * *
Link to Video - click here to watch the technical chart video
Split on May 5th 2017
Rexahn Pharmaceuticals, Inc. (the “Company”) announced today that it has effected a one-for-ten reverse split (the “Reverse Stock Split”) of the Company’s outstanding shares of common stock, together with a corresponding proportional reduction in the number of authorized shares of the Company’s capital stock (the “Authorized Share Reduction”). To effectuate the Reverse Stock Split and the Authorized Share Reduction, the Company filed a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware. Pursuant to and upon the effectiveness of the Amendment at 7:00 a.m., Eastern Standard Time, on May 5, 2017, each ten shares of the Company’s common stock, par value $0.0001 per share, issued and outstanding at the effective time were reclassified and combined into one share of common stock, par value $0.0001 per share, of the Company and the number of shares of common stock and preferred stock the Company is authorized to issue was reduced to 50 million and 10 million, respectively
Thanks. Clearly the trick is to flip by buying low / selling higher BEFORE the next R/S. It been close to 2 years now so another R/S may be in the making. Based on this management's style and historical behavior is anyone willing to speculate on whether we will soon see another R/S to help prevent delisting?
Does anyone know when the last time RNN executed a reverse split?
Wow with the reaction to this offering the stock price presplit is
.06 cents
don't hold your breath - how many times have we been here?
Looks like the results r good moving on up
* * $RNN Video Chart 01-14-2019 * *
Link to Video - click here to watch the technical chart video
Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium
Leadership Change...yeah who cares! Hopefully this new CEO can do something of significant value, like secure financing and buy back all the toxic debt. Stop trying to Increase the A/S, just to sell more convertible notes. This company has dug itself a hole that it needs to climb out of on its own. Shareholders are not subsidizing this anymore. How about finding a partner for phase 2-3 trials. This company has no money to make that happen. Maybe just sell the whole company and let us get some losses back or possibly even break even, because the hope of FDA approval is a lost forgone conclusion.
Is it over for Rnn new lows everyday
What is going on
agree - it was a direct offering though so technically the market didn't have to soak up the new shares. And it's still within the original 50 million OS - I'm just trying to make myself feel better. I don't believe it should have cratered like this but again, trying to make myself feel better.
No regard for the shareholder here. Almost got back in!!!thank God I didn’t
They r doing another presentation
This little buy rating is giving this a little kick. If management was smart they would cancel their f*ing meeting and release some positive data on their drugs, at minimum an update on the Chinese partnership. But that's asking a lot from these folks, I'm sure they will issue some shares to kill any momentum.
Totally agreed! It's pretty sad what this stock has become. If mgmt wants to increase the A/S, then offer a 2:1 split and let investors keep what little they have left. If they would have doubled the A/S at this last meeting and left all else the same, this thing would be back in the pennies. There is ZERO buying pressure. The potential is here for blockbuster cancer drugs, but the investors are not paying attention. A few years ago, someone on another board told me that it's about 5 years too early to have money in this stock. He was right and I should have listened.
Management devastated this stock. They had momentum in the right direction and just kicked it in the nards, multiple times. This will need some serious good news from the Chinese, if that partnership is even real.
The daily volume is pathetic. No real buyers or sellers. Likely dead until the end of August when the next vote happens. Shareholders shot down the 100mil share increase authorization. Will this 50mil pass? People have no confidence in management, we need new management blood. A new CEO would be a good start. By Zeus, hopefully they have irons in the works & there’s a good partnership/deal waiting to be announced to catch us all off guard. Otherwise it’s pps murder via discounted dilution. “Hope” is all RNN investors are left with.
The balls of this mgmt team. They do a 1 for 10 R/S when the stock has the 1st momentum in years and absolutely crush that. The valuation drops 63% since then, as it sits today, and they have the nerve to ask shareholders to approve doubling the authorized shares...WTF! NO!! Absolutely not!!!
Why not just do a 1 for 5 split back in May of last year...oh because this is just a fancy way of doing a 1 for 20 R/S and them taking more from the Shareholders. This is total BS and I really hope this didn't pass. They'll prob still find some way around us. But I definitely voted No and I hope everyone here did the same.
Painful - like watching liberals self implode with TDS.
Imminent Q2 catalysts:
Completed data from Phase 2a trial of RX-3117 as 3rd line treatment of metastatic bladder cancer patients
Interim clinical data from Phase 2a trial of RX-5902 in triple negative breast cancer patients
IEXG - 121,600 share offering just showed up again and disappeared. Same trade as a few days back before the drop - sure looks like signals to me.....
looks like I'm always the last one to know when to sell.....I wish I was in the big club. Did I miss something?
The ASCO data summary is already known. Volume is dry. Don’t expect much from the event. Hopefully management has a rabbit up their sleeve as they’re due to dilute any day now to raise funds and it will be at a discount to the pps at that time.
Big ask at 2.26 for 121,600 - not sure what that means, either someone wants to dump a large chunk or giving a signal for someone to cover a large short position.
Update: The exchange listing the order was IEXG, seems to have come off now.....
Presentation this weekend correct?
I get the feeling RNN will run today, the volume dried up on this small pullback. But today's behavior strikes me like it will creep up and then run.
Agreed on the .22. I had not read that peer review before. Found that fairly informative on the Chinese partnership. I have no idea what China's regulations are like but I'm sure it's not like the US. 30% of proceeds would be very nice -
Maybe we finally will get real news to move the stock up and hold the gains.
Nice move this past week but pre split it’s only .22
I wonder if this article is fueling the moves. I don't have an account or willing to create one.
https://www.bizjournals.com/baltimore/news/2018/05/15/md-biotech-firm-nears-market-with-two-cancer-drugs.html
That's how you finish the day and week....very nice
Things are progressing nicely not very slow. One day this will be a $20+ stock
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
https://seekingalpha.com/pr/17163439-rexahn-phase-2a-combination-study-rxminus-3117-abraxane-first-line-metastatic-pancreatic
Or another head fake. Hard to tell with this one. Half the run ups result in nothing, once in awhile there’s actual meat to it
Some good news must be coming?
moving again on no news -
Some good news must have leaked out. Big volume big move up before presenting at another conference
it's moving now - some big bids pushing it up. I'm gitty at .22 - almost to my break even point....almost.
200MA break bulls trying to push this higher
Volume is almost 1.5 million today. Something is going on... unless it’s being manipulated/pumped up.
covering before earnings? We all know earnings will be bad....unless we don't know something that's out there. I'm still curious about the Chinese partnership and the royalty payments. Let's hope those tests are going really well -
well that ended badly - wth.....
Today is a good follow through to yesterdays move. Solid move up without the explosive moves which never last - RNN has been at some of the lowest levels for so long it was only a matter of time before it moved up. It will be interesting how the second half of the day goes. More moves up or trickle back down?
Maybe news has leaked, maybe the testing in China is going really well and the expectation of a royalty payment?
Slow study rise the past few days, has news leaked or is this just being manipulated up
Followers
|
192
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3898
|
Created
|
06/17/08
|
Type
|
Free
|
Moderators |
http://www.rexahn.com/cms/
http://finance.yahoo.com/q/ks?s=RNN
Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.
Our clinical development pipeline consists of three novel compounds:
RX-3117 is a novel, oral, small molecule nucleoside compound. Once intracellularly activated (phosphorylated) by the enzyme UCK2, it is incorporated into the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells. Because UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues, RX-3117 offers the potential for a targeted anti-cancer therapy with an improved efficacy and safety profile, and we believe it has therapeutic potential in a broad range of cancers, including pancreatic, bladder, colon, and lung cancer. RX-3117 has received “orphan drug designation” from the U.S. Food and Drug Administration (“FDA”) and from the European Commission (“EC”) for pancreatic cancer.
RX-5902 (Supinoxin™) is a potential first-in-class small molecule inhibitor of phosphorylated-p68, a protein that we believe plays a key role in cancer cell growth, progression and metastasis through its interaction with beta-catenin. Phosphorylated p68, which is highly expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth. RX-5902 selectively blocks the interaction of phosphorylated p68 with beta-catenin, thereby decreasing the proliferation or growth of cancer cells in preclinical models. In addition, multiple pre-clinical models suggest that RX-5902 enhances the efficacy of immunotherapy. We have evaluated RX-5902 in a Phase 1 dose escalation study in patients with a diverse range of metastatic, treatment-refractory tumors, including breast, ovarian, colorectal, and neuro-endocrine tumors. In February 2017, we initiated a Phase 2a clinical study of RX-5902 in patients with metastatic triple negative breast cancer (“TNBC”).
RX-0201 (Archexin®) is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-0201 is the subject of a research and development collaboration with Zhejiang Haichang Biotechnology Co., Ltd. (“Haichang”) for the development of RX-0201 for hepatocellular carcinoma. RX-0201 has received orphan drug designation from the FDA for renal cell carcinoma (“RCC”), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer.
These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.
Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.
Rexahn Pipeline
Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.
Rick Soni, MBA
President and Chief Operating Officer
Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.
Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President and Chief Financial Officer
Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University
ANALYST COVERAGE
Roth Capital Partners, LLC
Joseph Pantginis, Ph.D.
646-358-1907
jpantginis@roth.com
Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718
ehe@maximgrp.com
H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546
afein@hcwco.com
INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |